We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

5 hedge funds and large institutions have $10.2K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2025 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% less funds holding

Funds holding: 7 → 5 (-2)

50% less capital invested

Capital invested by funds: $20.4K → $10.2K (-$10.2K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
5
Holders Change
-2
Holders Change %
-28.57%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AW
Atlas Wealth
Ohio
-$2.37K
2
LIA
LBMC Investment Advisors
Tennessee
-$1.78K
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$5.6K – – –
WPA
2
Wealth Preservation Advisors
Tennessee
$2.94K – – –
ACM
3
Academy Capital Management
Texas
$1.12K – – –
FS
4
Financial Symmetry
North Carolina
$570 – – –
AW
5
Atlas Wealth
Ohio
– -$2.37K -26,620 Closed
LIA
6
LBMC Investment Advisors
Tennessee
– -$1.78K -20,000 Closed

PVCT Hedge Fund Activity: Q4 2025 in Review

5 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q4 2025, worth a combined $10.2K — down 50% from $20.4K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of PVCT and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Atlas Wealth, exiting entirely with an estimated $2.37K sold.

  • 5 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q4 2025, down from 7 in Q3 2025.
  • Funds reported $10.2K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q4 2025, down 50% quarter-over-quarter.
  • 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q4 2025 and 2 closed out, a net change of -2 holders.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q4 2025 was Atlas Wealth, an estimated $2.37K sold.

Based on aggregated 13F filings for Q4 2025.